JNJ241206P160000
- 7.00
- 0.000.00%
Johnson & Johnson Newsroom
Why Is Johnson & Johnson (JNJ) Among the Dividend Kings You Should Consider?
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies
Why Dividend Aristocrats Like Walmart, ADP, and AbbVie Are Set to Outperform -- Barrons.com
Investors Heavily Search Johnson & Johnson (JNJ): Here Is What You Need to Know
Marjorie Taylor Greene Discloses Buys of AMD, Alphabet, Microsoft, Others
Express News | J&J: Mentor Memorygel Enhance Breast Implant Receives FDA Approval for Largest Size Breast Implants for Reconstruction
Express News | Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for Tremfya® (Guselkumab)
Express News | France has issued guidelines to support businesses in using ai.
Express News | The annual pharmaceutical imports value of Peking Tianzhu Comprehensive Bonded Zone is approximately 120 billion yuan.
Express News | Two innovative drugs from johnson & johnson have been included in the new national medical insurance catalog.
Investors in Johnson & Johnson (NYSE:JNJ) Have Seen Decent Returns of 30% Over the Past Five Years
Is Johnson & Johnson (JNJ) the Best Dividend Aristocrat Stock To Buy Right Now?
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
Johnson & Johnson To Go Ex-Dividend On November 26th, 2024 With 1.24 USD Dividend Per Share
November 24th (Eastern Time) - $Johnson & Johnson(JNJ.US)$ is trading ex-dividend on November 26th, 2024.Shareholders of record on November 26th, 2024 will receive 1.24 USD dividend per share on
Johnson & Johnson (JNJ.US) has submitted a regulatory application to the FDA for its antibody therapy to treat moderate to severe active ulcerative colitis.
Johnson & Johnson (JNJ.US) announced that it has submitted a supplemental Biological Product License Application (sBLA) to the FDA in the USA.
Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program
Express News | Johnson & Johnson is seeking approval from the FDA to use the subcutaneous induction therapy of TREMFYA (GUSELKUMAB) to treat ulcerative colitis.